AbbVie Inc. Operating Cash Flow

Operating Cash Flow of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending June 29, 2020 was $3.09 Billion (a -19.03% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow decreased by -32.18%
  • Annual Operating Cash Flow for 2019 was $13.3 Billion (a -0.77% decrease from previous year)
  • Annual Operating Cash Flow for 2018 was $13.4 Billion (a 34.81% increase from previous year)
  • Annual Operating Cash Flow for 2017 was $9.96 Billion (a 41.46% increase from previous year)
  • Twelve month Operating Cash Flow ending June 29, 2020 was $14.7 Billion (a 4.33% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 9.62% year-over-year
Trailing Operating Cash Flow for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$14.7 Billion $14.1 Billion $13.3 Billion $13.4 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of AbbVie Inc.

Most recent Operating Cash Flowof ABBV including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of AbbVie Inc.

AbbVie Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $3,089.0 $3,815.0
2019 $3,275.0 $4,555.0 $2,477.0 $3,017.0 $13,324.0
2018 $3,392.0 $4,524.0 $2,866.0 $2,645.0 $13,427.0
2017 $2,584.0 $3,271.0 $2,003.0 $2,102.0 $9,960.0
2016 $1,541.0 $1,454.0 $1,918.0 $2,128.0 $7,041.0
2015 $1,963.0 $2,155.0 $1,832.0 $1,585.0 $7,535.0
2014 $-578.0 $1,786.0 $1,717.0 $624.0 $3,549.0
2013 $1,245.0 $1,798.0 $2,037.0 $1,187.0 $6,267.0
2012 $941.0 $2,249.0 $1,561.0 $1,594.0 $6,345.0
2011 $1,048.76 $1,769.42 $2,147.06 $1,281.72 $6,247.0
2010 $4,976.16 $4,976.0
2009 $5,367.33 $5,367.34

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.